Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T01:54:33.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    A banner announces an NIH website transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-25T01:53:24.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The footer’s site revision number was updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T01:41:00.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1.
    Difference
    0.3%
    Check dated 2026-10-11T02:05:56.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    A vertical Feedback tab appears along the right edge of the page, while the study record continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-04T01:58:29.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error page with a small header, a Home link, and a site revision tag (Revision: v3.7.0). This indicates an access restriction rather than the expected study record details.
    Difference
    20%
    Check dated 2026-09-20T00:51:02.000Z thumbnail image

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.